In­cyte gets an­oth­er graft-ver­sus-host dis­ease drug ap­proval, this time with part­ner Syn­dax

In­cyte and part­ner Syn­dax Phar­ma­ceu­ti­cals on Tues­day se­cured reg­u­la­to­ry clear­ance to mar­ket a third-line chron­ic graft-ver­sus-host dis­ease treat­ment, or cGVHD.

The agency

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER